basic research The president of the Mexican Society of Cardiology sat down with us to share his view of the cardiology medical field in the country, why Mexico needs to collaborate more with other nations to promote awareness of cardiovascular diseases and how prevention is the solution to most health issues. …
basic research Considered one of the leading medical authorities in the country, David Kershenobich provides an overview about the new challenges faced by the Mexican healthcare system with the transition from infectious to chronic-degenerative diseases, how the institute is implementing new patient centered care models to encourage prevention of risk factors and…
biotech SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a cure for cancer’. Could you please introduce yourself Dr. Moon, and tell us how you became involved with SillaJen? …
Boehringer Ingelheim Javier Castro came from Boehringer Ingelheim’s headquarters to run the Peruvian affiliate in January 2015, bringing with him a wealth of experience necessary to take the company to the next level. He discusses market access, reimbursement and new launches that BI plans to bring to Peru. What are your…
UCB Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance of valuing innovation above cost in Korea. What have been the most notable differences between the market situations in…
Alexion Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put in place, and how Alexion is communicating with patients’ associations and medical community to raise awareness about ultra-rare diseases. …
Conference The director of Algeria’s only pharmaceutical fair speaks out about how he came to set up the event and how the local industry has evolved over time. Where did the idea for Siphal come from, and what challenges have you had to address? I went to pharmacology school in…
Ferring The country manager of a research-driven, specialty biopharmaceutical group offering treatments for infertility outlines his firm’s approach for the socially conservative Algerian market. Your promotion as general manager of Ferring Algeria is quite recent. Can you tell us what were your priorities during the first year and how do you…
access Healthcare should not be seen as an expenditure, but rather as an investment. Mexico’s former minister of health and current dean at the Harvard T.H. Chan School of Public Health discusses how Mexico is moving towards effective universal coverage, the challenges the system is facing and the issues that remain.…
reimbursement The country manager of a JNJ affiliated company advocates deploying electronic healthcare techniques to transform the reach of local practitioners and speaks out about the sort of local adaptations that need to be considered when introducing new products to the Algerian market. What is your evaluation of the Algerian pharmaceutical…
biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…
biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…
See our Cookie Privacy Policy Here